53710-78-4

Usage

Uses

1. Used in Chemical Synthesis:
1-(3-Chloropropyl)imidazole is used as a key intermediate in the synthesis of various organic compounds, particularly in the production of magnetic nanoparticles. These nanoparticles serve as catalysts for organic transformations, enhancing the efficiency and selectivity of chemical reactions.
2. Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(3-chloropropyl)imidazole is utilized as a building block for the development of new drugs, targeting a wide range of therapeutic areas. Its unique chemical structure allows for the creation of novel molecular entities with potential therapeutic benefits.
3. Used in Material Science:
1-(3-Chloropropyl)imidazole is also employed in the field of material science, where it contributes to the development of advanced materials with specific properties. These materials can be used in various applications, such as sensors, coatings, and advanced composites.
4. Used in Environmental Applications:
In environmental applications, 1-(3-chloropropyl)imidazole can be used to develop new technologies for pollution control and remediation. Its chemical properties make it suitable for the design of materials that can selectively adsorb and remove contaminants from air, water, and soil.

Upstream product

• 288-32-4 1H-imidazole 
• 109-70-6 1.3-chlorobromopropane 

Downstream Products

• 210917-98-9 3-[3-imidazo-1-ylpropyloxyl]-nitrobenzene 
• 1178894-47-7 3-(1-(3-(1H-imidazol-1-yl)propyl)-1H-indol-3-yl)-1-phenyl-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-1H-pyrrole-2,5-dione 
• 1178894-48-8 3-(5-methoxy-1-(3-(1H-imidazol-1-yl)propyl)-1H-indol-3-yl)-1-phenyl-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-1H-pyrrole-2,5-dione 
• 1178894-49-9 3-(5-bromo-1-(3-(1H-imidazol-1-yl)propyl)-1H-indol-3-yl)-1-phenyl-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-1H-pyrrole-2,5-dione 
• 1178894-50-2 3-(6-bromo-1-(3-(1H-imidazol-1-yl)propyl)-1H-indol-3-yl)-1-phenyl-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-1H-pyrrole-2,5-dione 
• 1178894-51-3 3-(6-fluoro-1-(3-(1H-imidazol-1-yl)propyl)-1H-indol-3-yl)-1-phenyl-4-(1H-pyrrolo[3,2-b]pyridin-1-yl)-1H-pyrrole-2,5-dione 
• 1178564-41-4 3-(1-methyl-1H-indol-3-yl)-4-(1-(3-(1H-imidazol-1-yl)propyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-1-phenyl-1H-pyrrole-2,5-dione 

Relevant academic research and scientific papers

Facile synthesis of polymerized ionic liquids with high thermal stability

Twelve main-chain-type polymerized ionic liquids that have alkylimidazolium cation units were prepared using simple synthetic processes. The polymers were prepared using the self-polymerization of a single monomer; no polymerization initiators were required. The thermal stability and solvent miscibility of these polymers were studied. Results show that the combined anions greatly influence the solubility and thermal stability of the polymers. Among these polymers, poly-alkylimidazolium bis(trifluoromethylsulfonyl)imide polymers exhibited the highest thermal stability (>400 °C), which makes them candidates for many applications.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The invention relates to the field of medicine, discloses new nitrogen heterocyclic derivatives, preparation method thereof and as medicament in particular as the treatment and prevention of treating tissue fibrosis of the medicament. The invention also discloses a pharmaceutically acceptable compound of the present invention comprise a pharmaceutical composition and methods for using the composition for the treatment of the human or animal tissue fibrosis of diseases, in particular for treating the human or animal renal interstitial fibrosis, glomerular sclerosis, hepatic fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, skin fibrosis, after the operation of adhering, benign prostate hypertrophy, bone-myocardial, scleroderma, multiple sclerosis, pancreas fibrosis, liver cirrhosis, myosarcoma, neurofibromatosis, interstitial pulmonary fibrosis, diabetic nephropathy, Alzheimer's disease or vascular fibrosis disease in use. (by machine translation)

Discovery and SAR of N-(1-((substituted piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide derivatives: 5-Hydroxytryptamine receptor 4 agonist as a potent prokinetic agent

A series of novel benzamide derivatives, altering the 4-fluorophenylalkyl moiety in cisapride, were synthesized as 5-HT4 receptor agonists, and SAR of these analogs was examined on in vitro and in vivo prokinetic activities. These compounds were synthesized for high 5-HT4 receptor binding affinities and low hERG affinities. Several types of analogs were obtained and screened for 5-HT4 binding, hERG blocking, agonism, and gastric emptying assessment. Among the analogues, compound 23g showed promising results compared with the other analogs with respect to gastric emptying rates in rats. Therefore, we suggest that it may be a clinical candidate for the development of a potent prokinetic agent to treat GI disorders.

Method for catalytically synthesizing N, N'-disubstituted urea derivative and imidazole derivative

The present invention relates to a green and efficient method for preparing an N, N'-disubstituted urea derivative and an imidazole derivative. The method for preparing the N, N'-disubstituted urea derivative by condensation of an aromatic amine with a carbonate ester comprises: by using ionic liquid loaded magnetic nanoparticles as a catalyst, at the temperature of 60-100 DEG C, and at a normal pressure, and in a condition of solvent-free, performing a condensing reaction on the aromatic amine and the carbonate ester for 8-14 hours to obtaina corresponding N, N'-disubstituted urea derivative; by using a magnetic nanoparticle-loaded ionic liquid as a catalyst and by using ethanol as a solvent, performing Michael addition reaction of a substituted imidazole and an electron-deficient olefin for 1-5 hours at the temperature of 10-50 DEG C and at a normal pressure to obtain a corresponding imidazole derivative, wherein the catalyst is as shown in the specification. Experiments verify that after the reaction is completed, the catalyst is recycled simply through an external magnetic field and can be repeatedly used for many times, but the activity is not obviously reduced. The catalytic system is simple in operation and high in yield, and the reusability is good, so that the method has a good industrial prospect.

Nitrogenous Heterocyclic Derivatives And Their Application In Drugs

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

Stille cross-coupling reactions with tin reagents supported on ionic liquids

New ionic-liquid-supported tin reagents were synthesized and used in Stille cross-coupling reactions. High yields of biaryls were obtained under low-temperature, solvent-free, ligand-free conditions, with simple purification techniques. Moreover, the tin compound could be recycled up to five times without significant loss of reactivity. An expanded catalytic cycle for the Stille cross coupling reaction is proposed in order to explain side products that were formed under certain reaction conditions.

Cyclic protein tyrosine kinase inhibitors

Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

Hexitol derivatives having vasodilative activity

Disclosed is a hexitol derivative represented by the formula (I): STR1 wherein Q represents a formula selected from the group consisting of STR2 wherein a represents NH, O or S; each of b, c and d independently represents CH or N; each of R1, R2, R3 and R4 independently represents hydrogen, lower alkyl, trifluoromethyl, aryl, lower alkanoyloxy, amino, lower alkylamino, lower alkanoylamino, lower alkanoyl, aroyl, halogen, nitro, (CH2)m OR 7, (CH2)m SR7, (CH2)m CO2 R7 where R7 represents hydrogen or lower alkyl and m represents an integer of 0 to 3; each of R5 and R6 independently represents hydrogen or lower alkyl; U represents >N-- or STR3 W represents a single bond, --O-- or --S--; X represents STR4 wherein each of Y1 and Y2 independently represents hydrogen, lower alkyl, hydroxyl, lower alkanoyloxy, nitrile or phenyl; or Y1 and Y2 are combined together to form oxygen; each of Y3 and Y4 independently represents hydrogen or lower alkyl; and l is an integer of 0 to 6, and where l is an integer of 2 to 6, each STR5 may be the same or different; Z represents hydrogen or nitro; and, n is 2 or 3 or a pharmaceutically acceptable salt thereof. The compounds show prominent coronary vasodilative activities, and are useful in treating angina pectoris and myocardial infarction.